77671-31-9 Usage
Description
Enoximone is a phosphodiesterase inhibitor indicated for selective use as a
cardiostimulant in heart transplant patient maintenance. It is currently being investigated
for other indications including acute congestive heart failure.
Originator
Merrell Dow (USA)
Uses
Enoximone is a phosphodiesterase inhibitor used in the treatment of congestive heart failure and is selective to phosphodiesterase 3. Potent PDE-3 inhibitor.
Brand name
Perfan IV
Biological Activity
Inhibitor of type III phosphodiesterase (PDE3). Increases intracellular cyclic AMP (cAMP) concentrations and enhances myocardial contractility. Also induces concentration-dependent vasodilation in vitro .
Biochem/physiol Actions
Selective phosphodiesterase III (PDE3) inhibitor. Prevents the degradation of cAMP by PDE. Increased cAMP results in enhanced contractility of the heart.
Check Digit Verification of cas no
The CAS Registry Mumber 77671-31-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,7,6,7 and 1 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 77671-31:
(7*7)+(6*7)+(5*6)+(4*7)+(3*1)+(2*3)+(1*1)=159
159 % 10 = 9
So 77671-31-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)
77671-31-9Relevant articles and documents
A simple synthesis of 4-aroyl-5-methyl-1H-imidazol-2(3H)-one derivatives (Enoxymone analogues) from aryl methyl ketones via enaminones
Bezensek, Jure,Groselj, Uros,Stare, Katarina,Svete, Jurij,Stanovnik, Branko
, p. 294 - 307 (2014/03/21)
Aryl methyl ketones 1a-e gave with N,N-dimethylacetamide dimethylacetal (DMADMA) (E)-1- aryl-3-(dimethylamino)-but-2-en-1-ones 2a-e. Substitution of the N,N-(dimethylamino) group in the reaction with ammonium acetate afforded the corresponding (Z)-3-amino-1-aryl-but-2-en-1- ones 3a-e. In the reaction of 3a-e with diethyl azodicarboxylate intermediates 4a-e were formed, which were, in most cases without isolation, cyclized into ethyl (5-aroyl-4-methyl-2-oxo-2,3- dihydro-1H-imidazol-1-yl)carbamates 5a-e. Hydrolysis of the ester group, followed by the decarboxylation and deamination of intermediates 6a-c,e produced 4-aroyl-5-methyl-1Himidazol- 2(3H)-ones 7a-c,e.
4-Aroylimidazol-2-ones and their use as pharmaceuticals
-
, (2008/06/13)
Novel 4-aroylimidazol-2-ones of the following general structure which are useful as antihypertensives, cardiotonics, antithrombotics, bronchodilators and uterospasmolytics STR1 wherein Ar is 2-furyl, 2-thienyl or phenyl, the latter of which may optionally
